Foreign Direct Investment (FDI) is a key driver of economic growth and globalization, involving direct ownership or control in Indian entities by non-resident individuals or entities. Since 2014, Indi...
With 2024 coming to a close and 2025 starting to take shape, the healthcare and pharmaceutical sectors appear set to build on the positive momentum accumulated in the last year. The seismic developments that characterized 2024 have emboldened these sectors to embrace emerging technologies, tackle pressing global health challenges and further solidify the ever-evolving regulatory landscape in the new year. In this regard, continued efforts to bring uniformity in the regulation of medical devices, introduction of a novel framework for evaluating the validity and accuracy of rapid diagnostic tests and further streamlining of the application procedure for clinical trials serve as cases in point which highlight the upward trajectory that the healthcare and pharmaceutical sectors have been on lately.
Against this backdrop, INDUSLAW’s Shantanu Jindel, Shweta Gupta, Harshit Kumar, Vatsal Agarwal, and @Abhinav present you this edition of ‘Checking the Pulse’, delving into key updates from December 2024 to January 2025 in the healthcare and pharmaceutical sectors, while also tapping on notable deals that have gained interest from the industry.
